Member Info for Noise

Yeah, you missed out sepsis and heart failure/rhythm problems...... not a pleasant drug, but possibly better than death.

Over to you, 201.... it really could do great things and upset the PR departments at certain biotechs.

Yes...although I don't know if many of us fully understand the half-life/dose-response to 201, I think it lasts a few hours in the blood, however I'm not clear how long it remains "active" for. I believe I read something which suggested it actually remained functionally active for much longer (binded to the SH3 SRC protein, preventing all sex hormone related growth).

I personally suspect that 4-8mg dosing is good enough, but the frequency of dosing is probably more interesting at this stage. I recall the early dosing was quite infrequent, perhaps allowing hormone-related growth to continue intermittently. I am intrigued at the thought of weekly dosing at 8mg......that's where I think we'll start to know if this is a decent drug, or a stellar one.

Frankly, based on datasets so far, as a patient I'd choose 201 over Xtandi on what we have been shown so far, the side effects of Xtandi are just so numerous and awful.

Although weirdly in that proactive article yesterday it refers to the VAL301 Endometriosis trial:

"In the prelims, which were largely a summary of the work carried out last year, it said it was aiming to get VAL301, a treatment of the gynaecological condition, endometriosis, into the clinic this year. However its plans would be “dependant on funding and regulatory clearance”, it added."

Apologies ratcliffe, my semantic structure was dire in that example.

I think you know what I mean (potentially 201 and 401 in phase 3 within a year or so, maybe, plus the 301 and 101 following up behind). With the obvious requirement that we can continued trading etc. etc.

Uncanny, yes that's about right. In percentage terms it sounds ridiculous, but in financial terms we are now summarily valued at £2m, despite 2x phase 3 cancer clinical trials and another 2 in the relative short term.

Taking a really stupid example, if VAL201 is only slightly useful for a very rare subset of patients, if 1000 patients treated at a cost £2k , that covers the MCAP of Valirx. Yet we have seen that it (apparently) appears to be safe and useful for many more patients, while likely commanding a far higher sale price.

Red or Blue pill?

For a change, let's spend half an hour on positives.

So....desperately close to June 2019 and VAL201 results reported to Valirx. If good, it's plausible that UCLH could continue the 2b/3 trial within 6 months if the partner is willing. It sounds like they have had interested parties for 201 sitting in the background for some time, it'll be interesting to see how good/bad/interesting the results are.

If 201 works, it could plausibly treat 100k patients per year at a solid sales price, so you only have to run a quick calculator on how a £2m company becomes a....well let's start with a £50m company and go from there.

I have no doubt it has been a tough year for Satu, but seriously, I worked for a previous international company with 8 offices, 3 manufacturing sites and an annual revenue of £100mpa with good profitability - the MD was paid £250kpa.

We could have avoided 40m shares this year if she had taken a sensible(ish) £125kpa salary. That is quite eye opening, as her research baby is Geneice, so it's not like VAL101 has progressed very far in the last 2 years.

Stage 1: Underpants.
Stage 3? Profit!

I cannot discount that was the purpose of the EHGO, I mean timing it to coincide with the 401/201 deals starting/concluding makes sense from a negotiating POV, as would terminating it early if it had the desired outcome.

It's an interesting question why Satu would terminate the EHGO deal early, or for renegotiation anyway.

Something must have changed which altered the business stance, cause she could not have gone into that deal blind, thinking there were good reasons to change it.

If so, what has fundamentally changed the strategy? Was she using the EHGO deal as leverage to show financial security and encourage a swift end to negotiations? Has that possibly concluded, or collapsed, resulting in a different situation? Very strange, but could be good or bad reasons.

Probably BS. Although we are overdue news on 401 so its not completely unrealistic a deal of some kind is being put together.

So you mean he's spammed up the ADVFN bb with an unsubstantiated rumour about a £75m deal for 401, plus another random rumour on Twitter?

I'd be very happy if Suzy has negotiated a £75m deal for 401, but I'm finding him a bit less than credible.

He's done what?

An interesting observation roses. I have been wondering when/where the AGM will be. Perhaps they are delaying it to include 201 commentary?

This is our last week in May 2019....roll on next month.

I would also really like an update on 401, it has been 2 months since we were informed that partners had signed up for the p3.

Marmited, dear god I am thankful to see a voice of sanity in the eternal buys vs sells argument. Thank you.

Not sure what they're angling with here. It sounds like they are just haggling around certain aspects. Clearly this hasn't been the ideal stock to back for a couple of years (ahem), but if I was being kind, I would suggest they are trying to ensure that EHGO do not unfairly gain from any price increases that could result if the 201 results are good.

Of course, they may not be good, plus all the other risks and uncertainties, but if they showed any improvement on the 4mg dosing range, the Valirx MCAP could stand to markedly improve (I'm not 100% clear how the equity/loans work in the case of an increased share price, based on RNS information so far).

PS I know we've had some unacceptable dilution, but who sold £1.42 of shares this morning?

One more week until June 2019 baby!

#givemedatanomnomnom

I always hate these holdings RNS. In general, I wish they would include a laymans paragraph saying what was happening. I don't want to read a long ramble of transactions

Badshah, yeah that's the lad I assumed it was.

Oh..roses, .if were talking about e-mail then I'm probably talking cod